MARTINS AZIENGBE: Open Payments
NPI 1659618908 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$363 in 11 payments from 6 companies in 2025. Trend: 2023 $0 · 2024 $88 · 2025 $363
Food & beverage: $363
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $142 |
| GlaxoSmithKline, LLC. | 3 | $86 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $78 |
| Phadia US Inc. | 1 | $22 |
| ABBVIE INC. | 1 | $18 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: Ozempic, JARDIANCE, TRELEGY ELLIPTA, AREXVY, ImmunoCAP, VRAYLAR, COBENFY.
Industry payments across DC — which companies pay providers there.
